$2.01
-0.055-2.66%
In chiusura: Nov 16, 4:00 PM EST
$1.96
-0.05-2.49%
Post-mercato: 7:21 PM EST
Niagen Bioscience (NAGE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $-0.01 | $-0.03 | 66.7 % |
| Q2 | Aug 4, 2026 | $0.01 | $0.02 | -50.0 % |
| Q1 | May 6, 2026 | $0.07 | $0.06 | 16.7 % |
| Q4 | Mar 4, 2026 | $0.03 | $0.01 | 200.0 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $27.19M | $32.89M | -17.3 % |
| Q2 | Aug 4, 2026 | $29.79M | $31.36M | -5.02 % |
| Q1 | May 6, 2026 | $31.47M | $30.73M | 2.43 % |
| Q4 | Mar 4, 2026 | $33.84M | $31.46M | 7.55 % |
Niagen Bioscience (NAGE) ha pubblicato l'ultima guidance il novembre 4, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $145.3M - $151.62M per il periodo.
Rispetto alle previsioni precedenti, Niagen Bioscience ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Niagen Bioscience ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Niagen Bioscience. 8
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.03 | $0.02 | $0.06 | $0.01 |
| Actual | $-0.01 | $0.01 | $0.07 | $0.03 |
| Surprise | +66.7% | -50.0% | +16.7% | +200.0% |
| Revenue | ||||
| Estimate | $32.9M | $31.4M | $30.7M | $31.5M |
| Actual | $27.2M | $29.8M | $31.5M | $33.8M |
| Surprise | -17.3% | -5.02% | +2.43% | +7.55% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.05 | $-0.02 | $0.01 | $0.01 |
| Revenue | ||||
| Consensus | $30.0M | $31.5M | — | — |
